open access

Ahead of print
Research paper (original)
Published online: 2021-09-03
Get Citation

Serum ROBO4 and CLEC14A: preliminary evaluation as diagnostic and progression biomarkers in colorectal cancer patients

Łukasz Pietrzyk, Kamil Torres
DOI: 10.5603/NJO.a2021.0052

open access

Ahead of print
Original article
Published online: 2021-09-03

Abstract

Introduction. Colorectal cancer (CRC) is an important global burden, and the discovery of biomarkers for screening and monitoring is a current challenge. The present study aimed to determine the serum concentration of ROBO4 and CLEC14A in CRC patients and assess the diagnostic and progression value of these biomarkers in CRC.

Material and methods. Serum samples were collected from 32 patients with CRC and from 16 healthy individuals. Blood serum of CRC patients were tested before and after surgery. Serum concentration of ROBO4 and CLEC14A were measured using ELISA tests.

Results. The serum concentrations of ROBO4 and CLEC14A were significantly higher in CRC patients than non-cancer controls. The sensitivitiy and specificity of ROBO4 and CLEC14A in distiguishing cancer patients from controls ranged from 71.9% to 100% and from 84.5% to 100%, respectively. The serum ROBO4 concentration was associated with the TNM stage, depth of invasion, and lymph node and distant metastases. The level of ROBO4 was statistically lower 3 months after the surgery, compared to the level noted prior to the operation.

Conclusions. Our preliminary study has provided evidence that ROOB4 and CLEC14A seem to be suitable biomarkers for clinical diagnostic purposes in colorectal cancer.

Abstract

Introduction. Colorectal cancer (CRC) is an important global burden, and the discovery of biomarkers for screening and monitoring is a current challenge. The present study aimed to determine the serum concentration of ROBO4 and CLEC14A in CRC patients and assess the diagnostic and progression value of these biomarkers in CRC.

Material and methods. Serum samples were collected from 32 patients with CRC and from 16 healthy individuals. Blood serum of CRC patients were tested before and after surgery. Serum concentration of ROBO4 and CLEC14A were measured using ELISA tests.

Results. The serum concentrations of ROBO4 and CLEC14A were significantly higher in CRC patients than non-cancer controls. The sensitivitiy and specificity of ROBO4 and CLEC14A in distiguishing cancer patients from controls ranged from 71.9% to 100% and from 84.5% to 100%, respectively. The serum ROBO4 concentration was associated with the TNM stage, depth of invasion, and lymph node and distant metastases. The level of ROBO4 was statistically lower 3 months after the surgery, compared to the level noted prior to the operation.

Conclusions. Our preliminary study has provided evidence that ROOB4 and CLEC14A seem to be suitable biomarkers for clinical diagnostic purposes in colorectal cancer.

Get Citation

Keywords

ROBO4; CLEC14A; biomarker; colorectal cancer; angiogenesis

About this article
Title

Serum ROBO4 and CLEC14A: preliminary evaluation as diagnostic and progression biomarkers in colorectal cancer patients

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Research paper (original)

Published online

2021-09-03

DOI

10.5603/NJO.a2021.0052

Keywords

ROBO4
CLEC14A
biomarker
colorectal cancer
angiogenesis

Authors

Łukasz Pietrzyk
Kamil Torres

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl